




BB

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |           |  |
|---|-----------|--|
| <b>(51) International Patent Classification <sup>6</sup>:</b><br><b>C12Q 1/68</b>   | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 98/54359</b><br><b>(43) International Publication Date:</b> 3 December 1998 (03.12.98)   |
| <b>(21) International Application Number:</b> PCT/GB98/01481<br><b>(22) International Filing Date:</b> 21 May 1998 (21.05.98)<br><b>(30) Priority Data:</b><br>9711040.7                      29 May 1997 (29.05.97)                      GB<br><b>(71)(72) Applicants and Inventors:</b> DUFF, Gordon [GB/GB]; 18 Ashgate Road, Sheffield S10 3BZ (GB). COX, Angela [GB/GB]; 2 Melbourn Road, Crookes, Sheffield S10 1NS (GB). CAMP, Nicola, Jane [GB/GB]; 26 Wynyard Road, Hillsborough, Sheffield (GB). DE GIOVINE, Francesco, Saverio [IT/GB]; 3 Tetney Road, Ranmoor, Sheffield S10 3GZ (GB).<br><b>(74) Agent:</b> AUSTIN, Hedley, William; Urquhart-Dykes & Lord, Alexandra House, Alexandra Road, Swansea SA1 5ED (GB). |           | <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |

(54) Title: PREDICTION OF INFLAMMATORY DISEASE ASSOCIATED WITH IL-1 GENELOCI POLYMORPHISMS



Polymorphic loci in the IL-1 gene cluster.

## (57) Abstract

Methods, assays and kits are disclosed for detecting a patient's susceptibility to an inflammatory disorder such as coronary artery disease, osteoporosis, nephropathy in diabetes mellitus, alopecia areata, Graves disease, systemic lupus erythematosis, lichen sclerosis, ulcerative colitis, diabetic retinopathy, periodontal disease, juvenile chronic arthritis particularly chronic iridocyclitis, psoriasis, insulin dependent diabetes and other diseases with an IL-1 genetic component. The methods comprise obtaining a biological sample from a patient and determining the presence or absence of a particular haplotype from the IL-1 gene cluster that is associated with an inflammatory disorder. Detection of at least one of the alleles in the haplotype indicates a susceptibility for the inflammatory disorder.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MR | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MT | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IS | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IT | Italy                                    | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | JP | Japan                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | KE | Kenya                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KG | Kyrgyzstan                               | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KR | Republic of Korea                        | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KZ | Kazakhstan                               | PT | Portugal                                     |    |                          |
| CN | China                    | LC | Saint Lucia                              | RO | Romania                                      |    |                          |
| CU | Cuba                     | LI | Licchtenstein                            | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LK | Sri Lanka                                | SD | Sudan  |    |                          |
| DE | Germany                  | LR | Liberia                                  | SE | Sweden                                       |    |                          |
| DK | Denmark                  |    |  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

PREDICTION OF INFLAMMATORY DISEASE ASSOCIATED  
WITH IL-1 GENE LOCI POLYMORPHISMS

**Background**

**1. Field of the Invention**

This invention relates to methods and kits for the identification of susceptibility to immunoinflammatory disorders or disorders modulated by IL-1 biologic activity. Specifically, the method involves the detection of at least one allele in an IL-1 haplotype, such as the IL-1 (44112332) haplotype or the IL-1 (33221461) haplotype, which is associated with inflammatory disorders, such as coronary artery disease, osteoporosis, nephropathy in diabetes mellitus, alopecia areata, Graves disease, systemic lupus erythematosus, lichen sclerosis, ulcerative colitis, diabetic retinopathy, periodontal disease, juvenile chronic arthritis, particularly chronic iridocyclitis, psoriasis, insulin dependent diabetes in DR3/4 patients, asthma, chronic inflammatory liver diseases, chronic inflammatory lung disease, lung fibrosis, liver fibrosis, as well as acute and chronic inflammatory diseases of the central nervous system, the cardiovascular system, the gastrointestinal system, the musculoskeletal system, the endocrine system, the skin and associated structure, the immune system, the hepato-biliary system, or any site in the body where pathology can occur with an "immune-inflammatory" component involving IL gene products irrespective of the initiating factors, eg: infectious agents, trauma, neoplasia, autoimmunity, idiopathic diseases, biologic toxins and noxious agents, and other diseases with an IL-1 loci genetic component.

**2. Description of the Background**

Genetic testing (also called genetic screening, genotyping or molecular diagnostics) can be defined broadly as the testing of nucleic acid of a patient in an analytical capacity to determine if a patient contains mutations (or alleles or polymorphisms) that either cause or increase

- 5 susceptibility to a disease state or are in "linkage disequilibrium" with the gene causing a disease state.

Linkage disequilibrium, refers to the tendency of specific alleles to occur together more frequently than would be expected by chance. Alleles at given loci are in equilibrium if the frequency of any particular set of alleles (or haplotype) is the product of their individual population  
10 frequencies. The cause of disequilibrium is often unclear. It can be due to selection for certain allele combinations, or to recent admixture of genetically heterogeneous populations. In addition, in the case of markers that are very tightly linked to a disease gene, an association of an allele (or group of linked alleles) with the disease gene is expected if the disease mutation occurred in the recent past, so that sufficient time has not elapsed for equilibrium to be achieved through recombination  
15 events in that small chromosomal region.

The early detection of a predisposition to genetic diseases presents the best opportunity for medical intervention. Early genetic diagnosis may improve the prognosis for a patient through supervision and early intervention before the clinically detectable disorder occurs.

In cases where patients with similar symptoms are treated with variable success, sophisticated  
20 genetic testing can differentiate individual patients with subtle or undetectable differences and can lead to more suitable individual treatments. Early intervention may involve methods such as gene therapy or treatment with IL-1 modulators. With the development of genetic testing, it is now possible to identify gene mutations which indicate a propensity to develop disease, even when the disease is of polygenic origin. The number of diseases that can be diagnosed by molecular  
25 biological methods continues to grow with increased understanding of the genetic basis of multifactorial disorders (*see e.g.*, United States Patent Nos. 4,582,788; 5,110,920; 4,801,531; 4,666,828; and 5,268,267).

## 5 The IL-1 Gene Cluster

The IL-1 gene cluster is located on the long arm of human chromosome 2 (2q13) and contains at least the genes for IL-1 $\alpha$  (IL1A), IL-1 $\beta$  (IL1B), and the IL-1 receptor antagonist (IL1RN) within a region of 430 Kb (Nicklin, *et al.*, *Genomics* 19: 382-4 (1994)). The agonist molecules, IL-1 $\alpha$  and IL-1 $\beta$ , have potent pro-inflammatory activity and are at the head of many  
10 inflammatory cascades. Their actions, often via the induction of other cytokines such as IL-6 and IL-8, lead to activation and recruitment of leukocytes into damaged tissue, local production of vasoactive agents, fever response in the brain and the hepatic acute phase response. All three IL-1 molecules bind to type I and to type II IL-1 receptors, but only the type I receptor transduces a signal to the interior of the cell. In contrast, the type II receptor is shed from the cell membrane and acts  
15 as a decoy receptor. The receptor antagonist and the type II receptor, therefore, are both anti-inflammatory in their actions.

Inappropriate production of IL-1 appears to play a central role in the pathology of many autoimmune and inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disorder, psoriasis, and others. In addition, there are stable inter-individual differences in the rates  
20 of production of IL-1, and some of this variation may be accounted for by genetic differences at IL-1 gene loci (Molvig, *et al.*, *Scand. J. Immunol.* 27:705-16 (1988); Pociot, *et al.*, *Eur. J. Clin. Invest.* 22: 396-402 (1992)). Thus, the IL-1 genes are reasonable candidates for determining part of the genetic susceptibility to inflammatory diseases, most of which have a multifactorial etiology with a polygenic component.

25 Certain alleles from the IL-1 gene cluster are known to be associated with particular disease states. For example, we have shown that IL1RN allele 2 is associated with coronary artery disease, osteoporosis (U.S. Application Nos. 08/813,416, 08/628,282), nephropathy in diabetes mellitus (Blakemore, *et al.*, *Hum. Genet.* 97(3): 369-74 (1996)), alopecia areata (Cork, *et al.*, *J.*

- 5 *Invest. Dermatol.* 104(5 Supp.): 15S-16S (1995)), Graves disease (Blakemore, *et al.*, *J. Clin. Endocrinol.* 80(1): 111-5 (1995)), systemic lupus erythamatosus (Blakemore, *et al.*, *Arthritis Rheum.* 37: 1380-85 (1994)), lichen sclerosis (Clay, *et al.*, *Hum. Genet.* 94: 407-10 (1994)), and ulcerative colitis (Mansfield, *et al.*, *Gastroenterol.* 106(3): 637-42 (1994)). IL1RN cluster allele 1 is associated with diabetic retinopathy (GB Application No. 9618960.0). Likewise, we have shown
- 10 that the IL1A allele 2 from marker -889 and IL1B(TaqI) allele 2 from marker +3953 are associated with periodontal disease (U.S. S/N 08/510,696). The IL1A allele 2 from marker -889 is also associated with juvenile chronic arthritis, particularly chronic iridocyclitis (McDowell, *et al.*, *Arthritis Rheum.* 38: 221-28 (1995)). The IL1B(TaqI) allele 2 from marker +3953 of IL1B is also associated with psoriasis and insulin dependent diabetes in DR3/4 patients (di Giovine, *et al.*,
- 15 *Cytokine* 7: 606 (1995); Pociot, *et al.*, *Eur J. Clin. Invest.* 22: 396-402 (1992)).

### Summary of the Invention

The present invention provides a novel method for the early prediction of a propensity to develop inflammatory disorders. It also provides kits for the early determination of

20 said propensity and methods for identifying additional alleles that are associated with these diseases or linked (in linkage disequilibrium) with the haplotype.

The method of predicting increased risk for diseases modulated by IL-1 biologic activity (herein termed inflammatory disorders) consists of detecting the presence of one or more alleles of an IL-1 haplotype, or alternatively, the entire haplotype may be detected. The IL-1

25 haplotype may be the IL-1 (44112332) haplotype, the IL-1 (33441461) haplotype, or any other haplotype from this region. Preferably, the haplotype is the IL-1 (44112332) haplotype. Having one or more of the alleles in an IL-1 haplotype indicates increased risk for a variety of inflammatory disorders. These include, but are not limited to, coronary artery disease, osteoporosis, nephropathy

5 in diabetes mellitus, alopecia areata, Graves disease, systemic lupus erythamatosus, lichen sclerosis, ulcerative colitis, periodontal disease, juvenile chronic arthritis particularly chronic iridocyclitis, psoriasis, insulin dependent diabetes in DR3/4 patients, diabetic retinopathy and other diseases with an IL-1 loci genetic component.

In particular, the IL-1 (44112332) haplotype is associated with the following  
 10 diseases: coronary artery disease, osteoporosis, nephropathy in diabetes mellitus, alopecia areata, Graves disease, systemic lupus erythamatosus, lichen sclerosis, and ulcerative colitis. The IL-1 (33221461) haplotype is associated with the following diseases: periodontal disease, juvenile chronic arthritis, psoriasis, insulin dependent diabetes, and diabetic retinopathy.

In another embodiment, the invention can be described as the following: isolating  
 15 nucleic acid from the patient, identifying one or more alleles present in the IL-1 gene cluster, and comparing the one or more alleles to a control sample. The control sample contains at least one allele from an IL-1 haplotype. Thus, a control sample contains one or more of the following alleles from the IL-1 (44112332) haplotype:

|    |                                    |                            |
|----|------------------------------------|----------------------------|
| 20 | allele 4 of the 222/223 marker     | (*132 mu PCR product),     |
|    | allele 4 of the gz5/gz6 marker     | (*91 mu PCR product),      |
|    | allele 1 of the -889 marker        | (contains an NcoI site),   |
|    | allele 1 of the +3953 marker       | (contains two TaqI sites), |
|    | allele 2 of the -511 marker        | (contains a Bsu36I site),  |
|    | allele 3 of the gaat.p33330 marker | (*197 mu PCR product),     |
| 25 | allele 3 of the Y31 marker         | (*160 mu PCR product),     |
|    | allele 2 of the VNTR marker        | (240 bp PCR product).      |

\* The sizes of microsatellite marker PCR products is given in mobility units which approximate the size in base pairs, but may vary according to the method of determination, as would be readily  
 30 ascertained by one of skill in the art. The markers positions are as indicated by in the references of Table 1.

The control sample may also contain the following alleles which may be part of the IL-1 (44112332) haplotype:

|    |   |                                   |
|----|---|-----------------------------------|
| 5  | allele 2 of the 1731 marker of the IL1RN gene | (A at position 1731),             |
|    | allele 2 of the 1812 marker of the IL1RN gene | (A at position 1812),             |
|    | allele 2 of the 1868 marker of the IL1RN gene | (G at position 1868),             |
|    | allele 2 of the 1887 marker of the IL1RN gene | (C at position 1887),             |
|    | allele 2 of the 8006 marker of the IL1RN gene | (contains an HpaII or MspI site), |
| 10 | allele 2 of the 8061 marker of the IL1RN gene | (lacks an MwoI site),             |
|    | allele 2 of the 9589 marker of the IL1RN gene | (contains an SspI site).          |

The markers positions are as indicated by Clay, *et al.* or Gausch, *et al.*

15                   The control sample may also contain the following alleles from the IL-1 (33221461) haplotype:

|    |                                    |                         |
|----|------------------------------------|-------------------------|
|    | allele 3 of the 222/223 marker     | (*130 mu PCR product),  |
|    | allele 3 of the gz5/gz6 marker     | (*88 mu PCR product),   |
|    | allele 2 of the -889 marker        | (lacks an NcoI site),   |
| 20 | allele 2 of the +3953 marker       | (contains a TaqI site), |
|    | allele 1 of the -511 marker        | (lacks a Bsu36I site),  |
|    | allele 4 of the gaat.p33330 marker | (*201 mu PCR product),  |
|    | allele 6 of the Y31 marker         | (*166 mu PCR product),  |
| 25 | allele 1 of the VNTR marker        | (412 bp PCR product).   |

Similarity of the identified alleles from the patient to the control sample indicates the patient's predisposition to inflammatory disease. The control sample may also be an allelic ladder comprised of a plurality of the above listed alleles and may also contain additional alleles from the above markers. There may be a plurality of control samples, each containing different alleles or sets of  
30 alleles.

Another embodiment of the invention is a kit for the detection of alleles that are predictive of inflammatory disease. The kit generally includes at least one oligonucleotide complementary to a DNA sequence in the IL-1 gene family and a control sample. The control sample contains an allele known to be associated with inflammatory disease, as described above.  
35 The control sample may contain the actual PCR products produced by amplification of said alleles, or alternatively may contain genomic or cloned DNA from an individual that carries an IL-1 haplotype.



5           The kit may also include a DNA sampling means, a DNA purification means, and PCR reagents. Further, the oligonucleotide may contain a detectable label. The following oligonucleotides, among others, may be present in the kit or used with the methods:

|    |                               |                      |
|----|-------------------------------|----------------------|
|    | ATGTATAGAATTCCATTCCTG         | (SEQ ID NO. 1),      |
|    | TAAAATCAAGTGTTGATGTAG         | (SEQ ID NO. 2),      |
| 10 | GGGATTACAGGCGTGAGCCACCGCG     | (SEQ ID NO. 3),      |
|    | TTAGTATTGCTGGTAGTATTCATAT     | (SEQ ID NO. 4),      |
|    | TGTTCTACCACCTGAACTAGG         | (SEQ ID NO. 5),      |
|    | TTACATATGAGCCTTCCATG          | (SEQ ID NO. 6),      |
|    | CTCAGGTGTCCTCGAAGAAATCAAA     | (SEQ ID NO. 7),      |
| 15 | GCTTTTTTGCTGTGAGTCCCG         | (SEQ ID NO. 8),      |
|    | TGGCATTGATCTGGTTCATC          | (SEQ ID NO. 9),      |
|    | GTTTAGGAATCTTCCCCTT           | (SEQ ID NO. 10),     |
|    | GAGGCGTGAGAATCTCAAGA          | (SEQ ID NO. 11),     |
|    | GTGTCCTCAAGTGGATCTGG          | (SEQ ID NO. 12),     |
| 20 | GGGCAACAGAGCAATGTTTCT         | (SEQ ID NO. 13),     |
|    | CAGTGTGTCAGTGTACTGTT          | (SEQ ID NO. 14),     |
|    | CTCAGCAACACTCCTAT             | (SEQ ID NO. 15),     |
|    | TCCTGGTCTGCAGGTAA             | (SEQ ID NO. 16),     |
| 25 | TTACGCAGATAAGAACCAGTTTGG      | (SEQ ID NO. 17),     |
|    | TTTCCTGGACGCTTGCTCACCAG       | (SEQ ID NO. 18),     |
|    | TTCTATCTGAGGAACAACCACTAGTAGC  | (SEQ ID NO. 19),     |
|    | CACCAGACTTGACACAGGACAGGCACATC | (SEQ ID NO. 20),     |
|    | CGACCCTCTGGGAGAAAATCCAGCAAG   | (SEQ ID NO. 21),     |
| 30 | ACACAGGAAGGTGCCAAGCA          | (SEQ ID NO. 22),     |
|    | TGCAGACAGACGGGCAAAGT          | (SEQ ID NO. 23),     |
|    | TTGTGGGGACCAGGGGAGAT          | (SEQ ID NO. 24), and |
|    | AGCCTGGCACTCTGCTGAAT          | (SEQ ID NO. 25).     |

35           Another embodiment of the invention provides a method of identifying inflammatory disorders associated with one or more alleles of an IL-1 haplotype, for example the IL-1 (44112332) haplotype. The method consists of gathering a first group of patients *without* a particular inflammatory disease, gathering a second group of patients *with* the inflammatory disease and genotyping the first and second groups at the IL-1 gene cluster. If an allele of the IL-1 haplotype  
40 is over represented in the second group as compared with the first group, it is identified as associated with the inflammatory disease.

5 Another embodiment of the invention provides a method of identifying additional alleles in linkage disequilibrium with an IL-1 haplotype, for example the IL-1 (44112332) haplotype. Additional alleles from the IL-1 gene cluster can be identified by sequence or restriction enzyme analysis of this region of the DNA. Linkage disequilibrium is then established by typing two loci and comparing the observed and expected haplotype frequencies, where the expected  
10 frequencies under the null hypothesis of no association are the products of the individual allele frequencies. This comparison can be done using the E.H. program of Xie and Ott (Handbook of Human Genetic Linkage, 1994, John Hopkins University Press, 188-98).

Yet another embodiment of the invention is an allelic ladder comprising alleles from the markers described herein.

15 Other embodiments and advantages of the invention are set forth in part in the description which follows, and will be obvious from this description, or may be learned from the practice of the invention.

#### **Description of the Drawings**

20 Figure 1 depicts the 8 markers in the IL-1 gene cluster and their approximate location.  
Figure 2 depicts the correlation between linkage disequilibrium and physical distance.

#### **Detailed Description**

As embodied and broadly described herein, the present invention is directed to methods for the detection of at least one allele of an IL-1 haplotype, including the IL-1 (44112332)  
25 haplotype or the IL-1 (33221461) haplotype, that is associated with inflammatory disorders.

The term 'marker,' as used herein, refers to a specific site in the genome which exhibits sequence variations between individuals. For example, herein are described at least 8 markers: the 222/223, gz5/gz6, -889, +3953, -511, gaat.p33330, Y31 and VNTR markers.

5           The term 'allele' refers to the different sequence variants found at given markers. For example, there are at least 5 alleles, 1 through 5, at the VNTR marker and there are at least 2 alleles at the -889 marker. The sequence variants may be single or multiple base changes, including insertions, deletions or substitutions or may be variable number of sequence repeats and the like.

          The term 'linkage disequilibrium' refers to the co-inheritance of two alleles at  
10 frequencies greater than would be expected from the separate frequencies of occurrence of each allele in a given control population. The expected frequency of occurrence of two alleles that are inherited independently is the frequency of the first allele multiplied by the frequency of the second allele. Alleles that co-occur at expected frequencies are said to be in 'linkage equilibrium.'

          The term 'haplotype' is a set of alleles that are inherited together as a group (are in  
15 linkage disequilibrium). As used herein, haplotype is defined to include those haplotypes that occur at statistically significant levels ( $p_{\text{corr}} \leq 0.05$ ).

          As used herein the phrase 'an IL-1 haplotype' refers to any haplotype in the IL-1 loci. It includes at least the IL-1 (44112332) haplotype and the (33221461) haplotype as described herein.

          As used herein, the phrase 'IL-1 (44112332) haplotype' refers to the haplotype  
20 consisting of at least:

          allele 4 of the 222/223 marker of IL1A;  
          allele 4 of the gz5/gz6 marker of IL1A;  
          allele 1 of the -889 marker of IL1A;  
          allele 1 of the +3953 marker of IL1B;  
25       allele 2 of the -511 marker of IL1B;  
          allele 3 of the gaat.p33330 marker;  
          allele 3 of the Y31 marker; and  
          allele 2 of the VNTR marker of IL1RN.

30       The phrase 'IL-1 (44112332) haplotype' also includes any additional alleles that are in linkage disequilibrium with this set of alleles. For example, the IL-1 (44112332) haplotype may also contain the following alleles:

          allele 2 of the 1731 marker of the IL1RN gene       (A at position 1731),

|    |   |                                   |
|----|---|-----------------------------------|
| 5  | allele 2 of the 1812 marker of the IL1RN gene | (A at position 1812),             |
|    | allele 2 of the 1868 marker of the IL1RN gene | (G at position 1868),             |
|    | allele 2 of the 1887 marker of the IL1RN gene | (C at position 1887),             |
|    | allele 2 of the 8006 marker of the IL1RN gene | (contains an HpaII or MspI site), |
|    | allele 2 of the 8061 marker of the IL1RN gene | (lacks an MwoI site), and         |
| 10 | allele 2 of the 9589 marker of the IL1RN gene | (contains an SspI site).          |

As used herein, the phrase 'IL-1 (33221461) haplotype' refers to the haplotype consisting of at least:

- 15 allele 3 of the 222/223 marker of IL1A;
- allele 3 of the gz5/gz6 marker of IL1A;
- allele 2 of the -889 marker of IL1A;
- allele 2 of the +3953 marker of IL1B;
- allele 1 of the -511 marker of IL1B;
- allele 4 of the gaat.p33330 marker;
- 20 allele 6 of the Y31 marker; and
- allele 1 of the VNTR marker of IL1RN.

The phrase 'IL-1 (33221461) haplotype' also includes any additional alleles that are in linkage disequilibrium with this set of alleles.

25 The phrase 'inflammatory disease' or 'inflammatory disorder,' as used herein, refers to those diseases associated with inheritance of an IL-1 haplotype. In addition to conventional diseases of inflammation, the term encompasses those diseases which are not traditionally thought of as inflammatory conditions, but which have an inflammatory component or are modulated by the IL-1 gene cluster, including certain infectious diseases, certain metabolic disorders, and certain

30 aspects of tumor growth, spread and control. Inflammatory disorders include, but are not limited to, coronary artery disease, osteoporosis, nephropathy in diabetes mellitus, alopecia areata, Graves disease, systemic lupus erythamatosus, lichen sclerosis, ulcerative colitis, diabetic retinopathy, periodontal disease, juvenile chronic arthritis particularly chronic iridocyclitis, psoriasis, insulin dependent diabetes in DR3/4 patients and other diseases with an IL-1 loci genetic component.

35 As used herein, the process of 'detecting alleles' is variously described as 'genotyping, determining or identifying an allele or polymorphism,' or any similar phrase. The

5 allele actually detected might be a disease-causing mutation, or a mutation that is in linkage disequilibrium with a disease-causing mutation. It will be manifest in the genomic DNA of a patient, but may also be detectable from RNA or protein sequences transcribed or translated from this region.

The phrase 'IL-1 gene cluster' or 'IL-1 loci' or 'IL-1 gene family,' as used herein,  
10 includes all the nucleic acid at or near 2q13 on chromosome 2, including the IL1A, IL1B and IL1RN genes and any other linked sequences.

By 'propensity,' 'predisposition' or 'susceptibility' for disease what is meant is that certain alleles are hereby discovered to be 'associated' with a given disease state. They are thus over represented in individuals with disease as compared to healthy individuals and indicate that  
15 these individuals are at higher risk for developing disease or may develop a more severe form or particular subset of disease type.

By 'microsatellite marker' what is meant is a marker whose alleles comprise different numbers of short repeat (< 5 bp) sequences.

By 'VNTR marker' what is meant is a marker whose alleles comprise different  
20 numbers of medium length repeat sequences. A specific VNTR marker from intron 2 of the IL1RN gene is described herein.

By 'biallelic marker' what is meant is a marker with only two known alleles.

The cytokines in the IL-1 gene cluster play a central role in the immune and inflammatory responses as well as a number of inflammatory diseases. The degree of linkage  
25 disequilibrium of the IL-1 gene cluster was investigated and found to be statistically significant at 95% confidence level across an approximately 400 Kb stretch of the region. A previously unrecognized IL-1 (44112332) haplotype and a IL-1 (33221461) haplotype were found in the

- 5 healthy population. The entire IL-1 (44112332) haplotype was found to be at an increased frequency in patients with nephropathy in diabetes mellitus.

The invention is directed to a method of predicting the propensity or predisposition of a patient to inflammatory disease by genotyping the patient's DNA at the IL-1 gene cluster. The patient's genotype is compared with a control sample that contains one or more alleles from an IL-1  
10 haplotype, such as the IL-1 (44112332) haplotype or the IL-1 (33221461) haplotype. The alleles include:

- |    |                                    |                            |
|----|------------------------------------|----------------------------|
|    | allele 4 of the 222/223 marker     | (*132 mu PCR product),     |
|    | allele 4 of the gz5/gz6 marker     | (*91 mu PCR product),      |
|    | allele 1 of the -889 marker        | (contains an NcoI site),   |
| 15 | allele 1 of the +3953 marker       | (contains two TaqI sites), |
|    | allele 2 of the -511 marker        | (contains a Bsu36I site),  |
|    | allele 3 of the gaat.p33330 marker | (*197 mu PCR product),     |
|    | allele 3 of the Y31 marker         | (*160 mu PCR product),     |
| 20 | allele 2 of the VNTR marker        | (240 bp PCR product).      |

\* The sizes of microsatellite marker PCR products is given in mobility units which approximate the size in base pairs, but may vary according to the method of determination, as would be readily ascertained by one of skill in the art.

The control sample may also contain the following alleles which may be part of the  
25 IL-1 (44112332) haplotype:

- |    |   |                                   |
|----|---|-----------------------------------|
|    | allele 2 of the 1731 marker of the IL1RN gene | (A at position 1731),             |
|    | allele 2 of the 1812 marker of the IL1RN gene | (A at position 1812),             |
|    | allele 2 of the 1868 marker of the IL1RN gene | (G at position 1868),             |
|    | allele 2 of the 1887 marker of the IL1RN gene | (C at position 1887),             |
| 30 | allele 2 of the 8006 marker of the IL1RN gene | (contains an HpaII or MspI site), |
|    | allele 2 of the 8061 marker of the IL1RN gene | (lacks an MwoI site),             |
|    | allele 2 of the 9589 marker of the IL1RN gene | (contains an SspI site).          |

The control sample may also contain the following alleles from the IL-1 (33221461)  
35 haplotype:

- |  |                                |                        |
|--|--------------------------------|------------------------|
|  | allele 3 of the 222/223 marker | (*130 mu PCR product), |
|  | allele 3 of the gz5/gz6 marker | (*88 mu PCR product),  |
|  | allele 2 of the -889 marker    | (lacks an NcoI site),  |

|    |                                    |                         |
|----|------------------------------------|-------------------------|
| 5  | allele 2 of the +3953 marker       | (contains a TaqI site), |
|    | allele 1 of the -511 marker        | (lacks a Bsu36I site),  |
|    | allele 4 of the gaat.p33330 marker | (*201 mu PCR product),  |
|    | allele 6 of the Y31 marker         | (*166 mu PCR product),  |
| 10 | allele 1 of the VNTR marker        | (412 bp PCR product).   |

These alleles are known to be associated with a variety of inflammatory disorders, such as coronary artery disease, osteoporosis, nephropathy in diabetes mellitus, alopecia areata, Graves disease, systemic lupus erythamatosus, lichen sclerosis, ulcerative colitis, diabetic retinopathy, periodontal disease, juvenile chronic arthritis particularly chronic iridocyclitis, psoriasis, insulin dependent

15 diabetes in DR3/4 patients and other diseases with an IL-1 loci genetic component.

The identification of a disease-associated haplotype (the set of alleles in linkage disequilibrium) will allow the investigator to begin to determine which of the alleles are causative, rather than merely linked to a disease-causing allele. This information can be used to design rational treatment approaches, including gene therapy and treatment with a variety of agents that modulate

20 the activity of the proteins produced by the IL-1 gene cluster. It is also possible that multiple mutations might each partially contribute to disease states for diseases of complex origin. Thus, if the mutations are additive or synergistic, the detection of these mutations would indicate even higher risk for the disease. Furthermore, the presence of disease-associated alleles in linkage disequilibrium will allow the diagnostic testing of more than one allele, which will help to eliminate

25 the possibility of false positive results.

Techniques for determining the presence of particular alleles may be nucleic acid techniques based on size or sequence, such as restriction fragment length polymorphism (RFLP), nucleic acid sequencing, or hybridization.

These techniques may also comprise the step of amplifying the nucleic acid before

30 analysis. Amplification techniques are known to those of skill in the art and include cloning, polymerase chain reaction (PCR), polymerase chain reaction of specific alleles (PASA), polymerase

5 chain ligation, nested polymerase chain reaction, and the like. Amplification products may be assayed in a variety of ways, including size analysis, restriction digestion followed by size analysis, detecting specific tagged oligonucleotide primers in the reaction products, allele-specific oligonucleotide (ASO) hybridization, sequencing, hybridization, and the like.

PCR based detection means include multiplex amplification of a plurality of markers  
10 simultaneously. For example, it is well known in the art to select PCR primers to generate PCR products that do not overlap in size and can be analyzed simultaneously. Alternatively, it is possible to amplify different markers with primers that are differentially labeled and thus can each be detected. One means of analyzing multiple markers involves labeling each marker with a different fluorescent probe. The PCR products are then analyzed on a fluorescence based automated  
15 sequencer. Of course, hybridization based detection allows the differential detection of multiple PCR products in a sample. Other techniques are known in the art to allow multiplex analyses of a plurality of markers.

Allele detection techniques may be protein based if a particular allele produces a protein with an amino acid variant. For example, epitopes specific for the amino acid variant can  
20 be detected with monoclonal antibodies. Likewise, it is possible to detect alleles if they are present in processed RNA by techniques that are known in the art.

Another embodiment of the invention is directed to diagnostic kits for detecting a propensity for inflammatory disease in a patient. The kits can be used pre- or post-symptomatically or prenatally. The diagnostic kit may comprise one or more oligonucleotides capable of hybridizing  
25 to nucleic acid from the IL-1 gene cluster. A number of assay formats are useful for genotyping using the provided oligonucleotides. The most common formats involve nucleic acid binding, such binding to filters, beads, or microtiter plates and the like. Techniques may include dot blots, RNA blots, DNA blots, PCR, RFLP, and the like.



5           The oligonucleotides may be a variety of natural and synthetic compositions such as synthetic oligonucleotides, restriction fragments, cDNAs, synthetic PNAs, and the like. The assay may also employ labeled oligonucleotides to allow ease of identification in the assays. Examples of labels which may be employed include radiolabels, enzymes, fluorescent compounds, streptavidin, avidin, biotin, magnetic moieties, metal binding moieties, antigen or antibody moieties, and the like. Oligonucleotides include the following:

|    |                               |                      |
|----|-------------------------------|----------------------|
|    | ATGTATAGAATTCCATTCCTG         | (SEQ ID NO. 1),      |
|    | TAAAATCAAGTGTTGATGTAG         | (SEQ ID NO. 2),      |
|    | GGGATTACAGGCGTGAGCCACCGCG     | (SEQ ID NO. 3),      |
|    | TTAGTATTGCTGGTAGTATTCATAT     | (SEQ ID NO. 4),      |
| 15 | TGTTCTACCACCTGAACTAGG         | (SEQ ID NO. 5),      |
|    | TTACATATGAGCCTTCCATG          | (SEQ ID NO. 6),      |
|    | CTCAGGTGTCCTCGAAGAAATCAAA     | (SEQ ID NO. 7),      |
|    | GCTTTTTTGTGCTGTGAGTCCCG       | (SEQ ID NO. 8),      |
|    | TGGCATTGATCTGGTTCATC          | (SEQ ID NO. 9),      |
| 20 | GTTTAGGAATCTTCCCCTT           | (SEQ ID NO. 10),     |
|    | GAGGCGTGAGAATCTCAAGA          | (SEQ ID NO. 11),     |
|    | GTGTCCTCAAGTGGATCTGG          | (SEQ ID NO. 12),     |
|    | GGGCAACAGAGCAATGTTTCT         | (SEQ ID NO. 13),     |
|    | CAGTGTGTCAGTGTACTGTT          | (SEQ ID NO. 14),     |
| 25 | CTCAGCAACACTCCTAT             | (SEQ ID NO. 15),     |
|    | TCCTGGTCTGCAGGTAA             | (SEQ ID NO. 16),     |
|    | TTACGCAGATAAGAACCAGTTTGG      | (SEQ ID NO. 17),     |
|    | TTTCCTGGACGCTTGCTCACCAG       | (SEQ ID NO. 18),     |
| 30 | TTCTATCTGAGGAACAACCACTAGTAGC  | (SEQ ID NO. 19),     |
|    | CACCAGACTTGACACAGGACAGGCACATC | (SEQ ID NO. 20),     |
|    | CGACCCTCTGGGAGAAAATCCAGCAAG   | (SEQ ID NO. 21),     |
|    | ACACAGGAAGGTGCCAAGCA          | (SEQ ID NO. 22),     |
|    | TGCAGACAGACGGGCAAAGT          | (SEQ ID NO. 23),     |
| 35 | TTGTGGGGACCAGGGGAGAT          | (SEQ ID NO. 24), and |
|    | AGCCTGGCACTCTGCTGAAT          | (SEQ ID NO. 25).     |

The kit may also include DNA sampling means such as the AmpliCard™ (University of Sheffield, Sheffield, England S10 2JF; Tarlow JW, *et al.* *J. of Invest. Dermatol.* 103:387-389 (1994)) and the like; DNA purification means such as cell lysis with SDS followed by proteinase K digestion, Nucleon™ kits, and the like; and PCR reagents, such as 10X reaction buffers, thermostable polymerase, dNTPs, and the like.

5           Another embodiment of the invention provides a method of identifying additional alleles in linkage with an IL-1 haplotype, for example the IL-1 (44112332) haplotype. Additional alleles from the IL-1 gene cluster can be identified by sequence analysis of this region of the DNA.

Alternatively, additional alleles can be identified by restriction enzyme analysis (for methods of identifying novel markers, see McDowell, *et al.*, *Br. J. Rheumatol.* **32**(Supp 1): 182 (1983); Wilson, *et al.*, *Hum. Molec. Genet.* **1**(5): 353 (1992); di Giovine, *et al.*, *Hum. Molec. Genet.* **1**(6): 450 (1992); and our paper, Clay, *et al.*, *Human Genetics* **97**(6): 723-26 (1996)). Sequencing or restriction enzyme analysis of the IL-1 gene cluster DNA from an IL-1 (44112332) haplotype carrier and comparison with sequences from non-carrier individuals will identify additional alleles that may be present in the haplotype. Alternatively, linkage disequilibrium can be established as described  
15 in Example 3, or by family studies.

The invention is also directed to methods for identifying additional inflammatory disorders that are associated with alleles from an IL-1 haplotype. Groups of patients with and without disease are genotyped and compared. In this way it is possible to show that the haplotype is associated with new inflammatory disorders.

20           The following example illustrates embodiments of the invention, but should not be viewed as limiting the scope of the invention.

#### Example 1   Genotyping

All human subjects were unrelated, Caucasian, healthy blood donors from Sheffield  
25 (n = 112). Subjects were typed at the loci indicated in Table 1.

5 Table 1. Markers Used in Haplotype Study

10

15

| Marker      | Gene                   | Reference  |
|-------------|------------------------|--|
| 222/223     | IL1A                   | Todd & Naylor, <i>Nucleic Acids Res.</i> 19: 3756 (1991)                     |
| gz5/gz6     | IL1A                   | Zuliani, <i>et al.</i> , <i>Am. J. Hum. Genet.</i> 46: 963-69 (1990)         |
| -889        | IL1A                   | McDowell, <i>et al.</i> , <i>Arth. &amp; Rheum.</i> 38:221-8 (1995)          |
| +3953       | IL1B                   | di Giovine, <i>et al.</i> , <i>Cytokine</i> 7(6): 606 (1995)                 |
| -511        | IL1B                   | di Giovine, <i>Hum. Molec. Genet.</i> 1(6):450 (1992)                        |
| gaat.p33330 | between IL1B and IL1RN | Murray, <i>et al.</i> , <i>Coop. Hum. Link. Center</i> , unpublished         |
| Y31         | between IL1B and IL1RN | Spurr, <i>et al.</i> , <i>Cytogenet. &amp; Cell Genet.</i> 73: 255-73 (1996) |
| VNTR        | IL1RN                  | Tarlow, <i>et al.</i> , <i>Hum. Genet.</i> 91: 403-4 (1993)                  |

The primer sequences and fluorescent labels used in PCR amplification of markers  
 20 were as in Table 2.

Table 2. Primer Sequence and Florescent Label for Genotyping

25

| Marker  | Label | Primer Sequence                          |
|---------|-------|--|
| 222/223 | HEX   | ATGTATAGAATTCCATTCCTG (SEQ ID NO. 1)     |
|         |       | TAAATCAAGTGTTGATGTAG (SEQ ID NO. 2)      |
| gz5/gz6 | FAM   | GGGATTACAGGCGTGAGCCACCGCG (SEQ ID NO. 3) |
|         |       | TTAGTATTGCTGGTAGTATTCATAT (SEQ ID NO. 4) |
| -889    | NONE  | TGTTCTACCACCTGAACTAGG (SEQ ID NO. 5)     |
|         |       | TTACATATGAGCCTTCCATG (SEQ ID NO. 6)      |
| +3953   | NONE  | CTCAGGTGTCCTCGAAGAAATCAAA (SEQ ID NO. 7) |
|         |       | GCTTTTTTGCTGTGAGTCCCG (SEQ ID NO. 8)     |
| -511    | NONE  | TGGCATTGATCTGGTTCATC (SEQ ID NO. 9)      |

| Marker           | Label | Primer Sequence                       |
|------------------|-------|---------------------------------------|
| 5<br>gaat.p33330 | FAM   | GTTTAGGAATCTTCCCACTT (SEQ ID NO. 10)  |
|                  |       | GAGGCGTGAGAATCTCAAGA (SEQ ID NO. 11)  |
|                  |       | GTGTCCTCAAGTGGATCTGG (SEQ ID NO. 12)  |
| Y31              | HEX   | GGGCAACAGAGCAATGTTTCT (SEQ ID NO. 13) |
|                  |       | CAGTGTGTCAGTGTACTGTT (SEQ ID NO. 14)  |
| VNTR             | NONE  | CTCAGCAACACTCCTAT (SEQ ID NO. 15)     |
|                  |       | TCCTGGTCTGCAGGTAA (SEQ ID NO. 16)     |

Reaction conditions were as described in Table 3.

Table 3. Reaction Conditions

| Marker      | Conditions  |
|-------------|---|
| 222/223     | 50 mM KCl, 10 mM Tris-HCl pH 9.0, 1.5 mM MgCl <sub>2</sub> , 200 :mM dNTPs, 25 ng primers, 50 ng template, 0.004% W-1 (Gibco-BRL) 0.2 u Taq, PCR was done at 30 cycles of 94°C for 1", 55°C for 1", 72°C for 1" |
| gz5/gz6     | as per marker 222/223, except 1 u of Perfect Match (StrataGene) was added   |
| -889        | per marker 222/223, except PCR was done for 1 cycle at 96°C for 1", 40 cycles of 94°C for 1", 46°C for 1" 72°C for 1" and 1 cycle of 72°C for 4", products were cleaved with NcoI for analysis                  |
| +3953       | as per marker 222/223, except PCR was done for 35 cycles with annealing at 67.5°C, products were cleaved with Taq 1 for analysis  |
| -511        | as per marker 222/223, except PCR was done for 1 cycle at 95°C for 2", 35 cycles of 95°C for 1", 53°C for 1" 74°C for 1" and 1 cycle of 74°C for 4", products were cleaved with Aval and Bsu36I for analysis    |
| gaat.p33330 | per marker 222/223  |
| Y31         | per marker 222/223  |
| VNTR        | per marker 222/223 except with 1.7 mM MgCl <sub>2</sub> , 1 cycle at 96°C for 1"; 30 cycles of 94°C for 1", 60°C for 1", 70°C for 1" and 1 cycle at 70°C for 2"   |

222/223, gz5/gz6, gaat.p33330 and Y31 PCR products were examined by agarose gel electrophoresis and the remainder of the PCR products were pooled according to the intensity of ethidium bromide staining. 2 µl of the pool was analyzed on an ABI 373A automated sequencer

5 and allele sizes were determined using the Genescan and Genotyper software. Alleles were globally binned using a simple computer program and numbered in order of size.

-889 PCR products were digested with NcoI and the resulting fragments sized on 8% PAGE. Allele 1 produces 83 and 16 bp fragments. Allele 2 produces a 99 bp fragment.

+3953 PCR products were digested with restriction enzyme Taq I. Allele 1 produces  
10 fragments of 97, 85 and 12 bp, and allele 2 produces fragments of 182 and 12 bp.

-511 PCR products were digested with AvaI and Bsu36I and the fragments were sized by 8% PAGE. Allele 1 produces 190 and 114 bp fragments when digested with AvaI and a 304 bp fragment when digested with Bsu36I. Allele 2 produces a 304 bp fragment when digested with AvaI and 190 and 114 bp fragments when digested with Bsu36I.

15 VNTR PCR products were sized by electrophoresis on 2% agarose gel at 90V for 45 minutes. Allele 1 has 4 repeats and the PCR product is 412 bp, allele 2 has 2 repeats and the PCR product is 240 bp, allele 3 has 3 repeats and the PCR product is 326 bp, allele 4 has 4 repeats and the PCR product is 498 bp, allele 5 has 6 repeats and the PCR product is 584 bp.

Intergenic distances were determined by estimation based on the insert sizes of  
20 relevant PAC clones from a contig spanning the IL-1 gene cluster (Nicklin, *et al.*, *Genomics* 19: 382-4 (1994); Nothwang *et al.* *Genomics (in press)*). Intragenic distances were determined from the relevant nucleotide sequence obtained from the GENBANK database.

#### Example 2 Method for Estimating Linkage Disequilibrium

25 Because four of the markers studied herein are multiallelic, a preliminary analysis was carried out to determine which allelic combinations between pairs of loci contributed to the greatest disequilibrium, in order that the disequilibrium would not be masked when the alleles were grouped into biallelic systems. The E.H. program of Xie and Ott (Handbook of Human Genetic

- 5 Linkage, 1994, John Hopkins University Press, 188-98), incorporated by reference herein, was used to estimate haplotype frequencies under  $H_0$  (no linkage) and  $H_1$  (allelic linkage allowed). It was found that the elaborate allele grouping strategy had some advantages over commonly used methods, in that disequilibrium was detected between almost all pairwise combinations of markers examined and there was good correlation between disequilibrium and physical distance.
- 10 More specifically, the E.H. program of Xie and Ott was used to determine maximum likelihood estimates of disequilibrium ( $D_{ij}$ ) between each pairwise combination of alleles, where  $D_{ij} = h_{ij} - p_i q_j$  are the frequencies for allele  $i$  at locus 1 and allele  $j$  at locus 2 respectively, and  $h_{ij}$  is the frequency of the haplotype  $ij$ . The program calculated maximum likelihood values for the haplotype frequencies (and hence allele frequencies) under  $H_0$  (no association) and haplotype
- 15 frequencies under  $H_1$  (allelic association allowed).

For markers with greater than two alleles, the E. H. estimate for allele frequencies correlated poorly with the allele frequencies as estimated directly from the sample population, and therefore gave no confidence to the  $D_{ij}$  estimates given. It was therefore necessary to group alleles of the multi-allelic markers into a biallelic system. Analysis of the markers in a biallelic format has

20 the added advantages that the notation  $\hat{D}_{ij}$ ,  $p_j$ , and  $q_j$  can be simplified to  $\hat{D}$ ,  $p$ , and  $q$  respectively, where  $p$  and  $q$  are defined to be the frequencies of the rarer alleles at both loci (such that without loss of generality  $p \leq q \leq 0.5$ ), and  $\hat{D}$  is the estimated disequilibrium between those alleles.

Under a biallelic system, power is also much simpler to determine using equations as detailed by Hill (Hill, *Heredity*, 33: 229-39 (1974)). In addition, the sign of  $\hat{D}$  becomes

25 informative, such that  $\hat{D} > 0$  when the rarer alleles at each of the two loci are associated, and  $\hat{D} < 0$  when the rare allele at one locus is associated with the common allele at the other locus.

Because the method of allele grouping clearly affected the power to detect disequilibrium (Zouros, *et al.*, *Genet.* 85: 543-50 (1977); Weir, *et al.*, *Genet.* 88: 633-42 (1976)),

5 a preliminary analysis was conducted to ensure that the grouping did not mask disequilibrium between subsets of alleles. In this analysis,  $\delta_{ij} = (O'_{ij} - E_{ij})/\sqrt{E_{ij}}$  was calculated for each haplotype, where  $E_{ij}$  is the expected number of haplotypes  $ij$  assuming equilibrium ( $E_{ij} = 2n p_i q_j$ , where  $n$  = number of individuals in the study), and  $O'_{ij}$  is a basic estimate for the observed haplotype count determined as follows. All genotypes that could be unambiguously resolved were haplotype  
 10 counted. Each double heterozygote ( $i_1 i_2 / j_1 j_2$ ) could be resolved into two possible haplotype sets,  $[i_1 j_1, i_2 j_2]$  or  $[i_1 j_2, i_2 j_1]$ . Using the haplotype frequencies as estimated from the unambiguous haplotype count, the probability of each set was calculated and used as a "partial" count. In this way the ambiguous genotypes were also haplotype counted, and the total counts (ambiguous plus unambiguous) constituted the  $O'_{ij}$ 's used in  $\delta_{ij}$ . Once established, the magnitude and sign of the  $\delta_{ij}$ 's  
 15 were used to determine which allelic combinations showed greatest deviation from the null hypothesis of no association. This information was used to group alleles at the multiallelic loci into biallelic systems to enable efficient use of the E.H. program.

In order to compare the degree of disequilibrium between different pairwise combinations of loci, a frequency independent measure of disequilibrium ( $\tilde{D}$ , the proportion of  
 20 maximum possible disequilibrium in the given direction) was calculated, where  $\tilde{D} = \hat{D}/|D_{\max}|$  (Thompson, *et al.*, *Am. J. Hum. Genet.* 42: 113-24 (1988)). The relationship between  $p$  and  $q$  are such that  $p \leq q \leq 0.5$ , and it can therefore be written that  $-pq \leq D \leq p(1-q)$  such that when  $\hat{D} < 0$ ,  $D_{\max} = -pq$  and when  $\hat{D} > 0$ ,  $D_{\max} = p(1-q)$ . Output from the E.H. program included log-likelihoods for the maximum likelihood parameter values under  $H_0$  and  $H_1$ , and since  $-2 \ln (L_0/L_1) \sim \chi^2_1$ , where  
 25  $L_0$  and  $L_1$  are the likelihoods under  $H_0$  and  $H_1$ ,  $p$ - values could then be determined for each test.

The asymptotic variance for  $\hat{D}$ , under  $H_0: D = 0$  and  $H_1$  were computed using the formula as defined by Hill (*Heredity* 33: 229-39 (1974)) for genotypic data. Using these, the power for each pairwise comparison could be calculated.

5 Common haplotypes containing all 8 loci were identified from the preliminary analysis of  $\delta_{ij}$  described above, and backed up by the magnitude and sign of the disequilibria once the alleles at the multiallelic loci had been grouped. For these loci, the allele in the group which contributed most to the disequilibrium has been identified on the haplotype. To estimate the population haplotype frequencies, rates of carriage of at least one copy of the relevant alleles in the population were determined. These do not represent true haplotypes since phase is unknown. Monte Carlo simulation techniques were used to test for significant deviation from a simulated null distribution for these combined carriages under the assumption of no association.

### Example 3 Estimation of Linkage Disequilibrium in the IL-1 Gene Cluster

15 A number of biallelic and multiallelic markers in and around the IL-1 genes have been identified. However, the extent of linkage disequilibrium between the markers, and the prevalence of multimarker haplotypes in the general population have not until now been identified.

Figure 1 shows the relative positions of the 8 marker loci used in this study. DNA samples from 212 unrelated healthy volunteers were genotyped for each of these markers, and the resulting estimates of allele frequencies are shown in Table 4.

**Table 4. Estimated frequencies of marker alleles**

| 222/223    | freq. | gz5/gz6   | freq. | -889     | freq. | +3953      | freq. |
|------------|-------|-----------|-------|----------|-------|------------|-------|
| 1 (126 bp) | 0.005 | 1 (79 bp) | 0.003 | 1 (NcoI) | 0.714 | 1 (2 TaqI) | 0.812 |
| 2 (128 bp) | 0.018 | 2 (82 bp) | 0.005 | 2        | 0.286 | 2          | 0.188 |
| 3 (130 bp) | 0.378 | 3 (88 bp) | 0.676 |          |       |            |       |
| 4 (132 bp) | 0.299 | 4 (91 bp) | 0.316 |          |       |            |       |
| 5 (134 bp) | 0.016 |           |       |          |       |            |       |
| 6 (136 bp) | 0.208 |           |       |          |       |            |       |



|    |             |       |             |       |             |       |       |       |
|----|-------------|-------|-------------|-------|-------------|-------|-------|-------|
| 5  | 222/223     | freq. | gz5/gz6     | freq. | -889        | freq. | +3953 | freq. |
|    | 7 (138 bp)  | 0.055 |             |       |             |       |       |       |
|    | 8 (140 bp)  | 0.003 |             |       |             |       |       |       |
|    | 9 (142 bp)  | 0.010 |             |       |             |       |       |       |
|    | 10 (144 bp) | 0.008 |             |       |             |       |       |       |
| 10 | *total      | 384   |             | 392   |             | 398   |       | 398   |
|    | -511        | freq. | gaat.p33330 | freq. | Y31         | freq. | VNTR  | freq. |
|    | 1           | 0.618 | 1 (189 bp)  | 0.658 | 1 (148 bp)  | 0.092 | 1     | 0.744 |
|    | 2 (Bsu36I)  | 0.382 | 2 (193 bp)  | 0.002 | 2 (158 bp)  | 0.008 | 2     | 0.256 |
|    |             |       | 3 (197 bp)  | 0.255 | 3 (160 bp)  | 0.454 |       |       |
|    |             |       | 4 (201 bp)  | 0.084 | 4 (162 bp)  | 0.062 |       |       |
|    |             |       |             |       | 5 (164 bp)  | 0.003 |       |       |
|    |             |       |             |       | 6 (166 bp)  | 0.122 |       |       |
|    |             |       |             |       | 7 (168 bp)  | 0.035 |       |       |
|    |             |       |             |       | 8 (170 bp)  | 0.030 |       |       |
|    |             |       |             |       | 9 (172 bp)  | 0.095 |       |       |
|    |             |       |             |       | 10 (174 bp) | 0.087 |       |       |
|    |             |       |             |       | 11 (176 bp) | 0.003 |       |       |
|    |             |       |             |       | 12 (178 bp) | 0.011 |       |       |
|    |             | 398   |             | 404   |             | 370   |       | 398   |

- 25 \*number of chromosomes analyzed  
Note - Allele names (and sizes) are given in boldface.

To determine the linkage disequilibria between pairwise combinations of loci, the computer program of Xie and Ott was used. This program was found to be most efficient when used with biallelic systems, therefore alleles at the multiallelic loci were grouped in the most appropriate way for each pairwise comparison, such that disequilibrium between subsets of alleles was not masked.

In Table 5, the disequilibria between pairs of loci are expressed as  $\tilde{D}$ , the ratio of  $\hat{D}$  to its maximum value  $D_{\max}$  and are shown together with the approximate physical distances between the loci in kilobase pairs.

5 Table 5. Disequilibrium ( $\tilde{D} = \hat{D} / |D_{\max}|$ ) and physical distances between markers

|             |         |             |        |        |
|-------------|---------|-------------|--------|--------|
|             | 222/223 | gz5/gz6     | -889   | +3953  |
| 222/223     | -       | +0.872      | +0.829 | +0.710 |
| gz5/gz6     | 2.5     | -           | -0.889 | -0.695 |
| -889        | 7       | 4.5         | -      | +0.804 |
| 10 +3953    | 55      | 55          | 50     | -      |
| -511        | 60      | 60          | 55     | 4.5    |
| gaat.p33330 | 260     | 260         | 255    | 205    |
| Y31         | 310     | 310         | 305    | 255    |
| VNTR        | 380     | 380         | 375    | 325    |
| 15          | -511    | gaat.p33330 | Y31    | VNTR   |
| 222/223     | +0.535  | +0.433      | +0.364 | -0.499 |
| gz5/gz6     | +0.540  | +0.517      | -0.503 | +0.286 |
| -889        | -0.264  | +0.337      | +0.318 | -0.207 |
| +3953       | -0.617  | +0.409      | -0.475 | -0.439 |
| 20 -511     | -       | +0.691      | -0.456 | +0.448 |
| gaat.p33330 | 200     | -           | +0.639 | +0.442 |
| Y31         | 250     | 50          | -      | -0.765 |
| VNTR        | 320     | 120         | 70     | -      |

25 Note - disequilibrium values are shown at the top right, approximate physical distances in Kb are shown at the bottom left. Intergenic distances are given to the nearest 5 Kb.

Table 6 shows the power to detect 50%  $D_{\max}$  for each locus combination, and the p values for each corresponding D.

30 Table 6. Power to detect 50%  $D_{\max}$  and p values of  $-2\ln(L_0/L_1)$

|             |                          |                          |                           |                           |
|-------------|--------------------------|--------------------------|---------------------------|---------------------------|
|             | 222/223                  | gz5/gz6                  | -889                      | +3953                     |
| 22/223      | -                        | ~100 (+)                 | ~100(+)                   | 98(+)                     |
| gz5/gz6     | $<1 \times 10^{-10}$     | -                        | 87(-)                     | 60(-)                     |
| -889        | $<1 \times 10^{-10}$     | $\sim 3 \times 10^{-6}$  | -                         | ~100(+)                   |
| 35 +3953    | $\sim 1 \times 10^{-7}$  | $\sim 9 \times 10^{-3}$  | $<1 \times 10^{-10}$      | -                         |
| -511        | $\sim 9 \times 10^{-10}$ | $\sim 4 \times 10^{-10}$ | $\sim 9.4 \times 10^{-2}$ | $\sim 2.6 \times 10^{-2}$ |
| gaat.p33330 | $\sim 9 \times 10^{-6}$  | $\sim 2 \times 10^{-9}$  | $\sim 1.7 \times 10^{-2}$ | $\sim 5 \times 10^{-4}$   |
| Y31         | $\sim 1 \times 10^{-4}$  | $\sim 4 \times 10^{-4}$  | $\sim 6 \times 10^{-4}$   | $\sim 1 \times 10^{-7}$   |

|    |             |                      |                      |                      |                        |
|----|-------------|----------------------|----------------------|----------------------|------------------------|
|    |             | 222/223              | gz5/gz6              | -889                 | +3953                  |
| 5  | VNTR        | $-1 \times 10^{-3}$  | $-1 \times 10^{-3}$  | $*-3 \times 10^{-1}$ | $*-1.2 \times 10^{-1}$ |
|    |             | -511                 | gaat.p33330          | Y31                  | VNTR                   |
|    | 22/223      | -100(+)              | -100(+)              | -100(+)              | 93(-)                  |
|    | gz5/gz6     | -100(+)              | -100(+)              | 98(-)                | -100(+)                |
|    | -889        | 96(-)                | 89(+)                | -100(+)              | 78(-)                  |
| 10 | +3953       | 79(-)                | 97(+)                | -100(+)              | 52(-)                  |
|    | -511        | -                    | -100(+)              | -100(-)              | -100(+)                |
|    | gaat.p33330 | $<1 \times 10^{-10}$ | -                    | 49(+)                | -100(+)                |
|    | Y31         | $-2 \times 10^{-4}$  | $*-7 \times 10^{-3}$ | -                    | 89(-)                  |
|    | VNTR        | $-8 \times 10^{-6}$  | $-1 \times 10^{-9}$  | $2 \times 10^{-7}$   | -                      |

15

Note - Power is shown at the top right with the sign of disequilibrium in brackets; pointwise p-values are shown (uncorrected) at the bottom left. For an overall significance level of  $p = 0.05$ , pointwise significance level is 0.0018 for 28 comparisons.

20 \* Not significant at  $p = 0.0018$  threshold

Significant linkage disequilibrium ( $p_{\text{corr}} < 0.05$ ) was detected between most combinations of loci, with only a few exceptions. These include the comparisons between the VNTR and the more distant biallelic markers, +3953, and -889, in which the disequilibrium is in the negative direction and consequently the power is reduced (Table 6). The correlation between

25 disequilibrium  $\tilde{D}$  and physical distance was  $r = -0.752$  ( $p < 0.0001$ , one tailed) (Figure 2).

In order to compare different grouping methods for the multiallelic markers,  $\tilde{D}$  was calculated for all the comparisons involving 222/223 using two additional grouping strategies. The first of these was a "common allele versus the rest" approach, and the second was a grouping based on allele size, using the bimodal distribution of allele frequency versus size which was observed for

30 all the multiallelic markers examined. The results of this analysis are shown in Table 7, where  $\tilde{D}$  values for the three grouping methods are compared.

5 Table 7.  $\tilde{D}$  values for three methods of grouping alleles at the multiallelic marker loci

|             | $\delta_{ij}$ | common vs. rest | allele size |
|-------------|---------------|-----------------|-------------|
| gz5/gz6     | 0.87          | 0.79            | 0.77        |
| -899        | 0.83          | 0.81            | 0.98        |
| +3953       | 0.71          | 0.74            | 0.77        |
| -511        | 0.54          | *0.15           | 0.61        |
| gaat.p33330 | 0.43          | *0.03           | 0.53        |
| Y31         | 0.36          | * 0.12          | 0.16        |
| VNTR        | 0.5           | 0.48            | * 0.04      |

Note - Values are given for the disequilibrium between 222/223 and the other markers listed.

15 \* indicates not significant at  $p = 0.05$  level, even before correction for multiple testing.

It can be seen that the disequilibrium is not detected in several instances using these other grouping strategies, notably 222/223 with -511 and gaat.p33330 in the common versus rest approach, 222/223 with Y31 in both the common versus rest and allele size approaches, and 222/223 with VNTR in the allele size approach.

20 Examination of which alleles of the multiallelic loci were contributing greatest to the disequilibrium, from the determination of  $\delta_{ij}$ , revealed the existence of 2 haplotypes containing alleles of all 8 loci. These were confirmed by examination of the haplotype frequencies and disequilibrium values obtained after the grouping. The first haplotype: alleles 44112332 (expressed in chromosome order, see Fig. 1) is the most common (carriage of 34/198), and is present 7 times  
 25 more frequently than expected (expected = 4.5/198) ( $p < 0.000001$ ). The second haplotype: alleles 33221461 (carriage of 2/206) was present 4 times more frequently than expected (expected = 0.5/206), but this was not statistically significant ( $p \sim 0.106$ ). However, examination of a larger sample size might assist increase the statistical significance of this finding.

The data presented indicate a significant degree of linkage disequilibrium across an  
 30 approximately 400 Kb stretch of chromosome 2q13. The disequilibrium was strong both for the three markers within the IL-1 $\alpha$  gene, as might be expected, but was also strong between some of the

5 more distantly separated markers (-899/+3953;  $\tilde{D} = +0.804$ , physical distance = 50 Kb) (Table 6). However,  $\tilde{D}$  was considerably diminished between the extreme ends of the cluster. Within the IL-1  $\beta$  gene, a moderate value of  $\tilde{D}$  (+3953/-511;  $\tilde{D} = -0.617$ ) was obtained, although this was not significant when corrected for multiple comparisons, probably reflecting the reduction in power when disequilibrium is in the negative direction (Thompson, *et al.*, *Am J. Hum. Genet.* 42: 113-24  
10 (1988)).

Overall, there is a good correlation between physical distance and linkage disequilibrium (Figure 2);  $r = -0.752$ . The reliability of  $r$  itself depends partly on the reliability of the estimates of both physical distance and  $\tilde{D}$ . Over the short distances, the physical distances are accurate since they are determined from known DNA sequence, whereas the longer range estimates  
15 are less precise. The power can be taken tentatively as one indicator of the reliability of  $\tilde{D}$ , since if power is low this indicates that the sample size was too small, and with low sample sizes the estimates for  $\tilde{D}$  may be unreliable.

The success of the elaborate grouping strategy is indicated by Table 7, which shows several instances where disequilibrium between particular loci is apparently low or not detected  
20 when other commonly used grouping methods are employed. The disadvantages of the grouping strategy used here are that it is rather laborious since the information used for the grouping was based on an approximate estimate of the "observed" haplotype frequencies (see Example 2). For the more polymorphic markers the higher heterozygosity meant that the estimate of  $\delta_{ij}$  was less precise since there was a higher proportion of ambiguous haplotypes. Notwithstanding this  
25 drawback, care was taken to take into account both the sign and magnitude of  $\delta_{ij}$ , and the frequencies of the alleles concerned.

The method could be simplified, in a sufficiently large study, by just considering the unambiguous haplotypes when determining the grouping. The determination of  $\delta_{ij}$  uses the

5 maximum amount of prior knowledge for the grouping of the multiallelic markers, and this may be the reason why disequilibrium between almost all pairwise combinations of markers was detected.

The two haplotypes containing all 8 markers, as well as other shorter haplotypes, are of particular interest since it is likely that particular combinations of alleles of the IL-1 genes may act in concert to determine an overall inflammatory phenotype. An understanding of which markers  
10 are in strong linkage disequilibrium not only allows for more rational design of genetic studies but also may provide clues to disease mechanism.

Additional alleles may also be part of the IL-1 (44112332) haplotype. We have previously shown that 5 novel markers were associated with allele 2 of the VNTR marker of the IL1RN gene (Clay, *et al.*, *Hum. Genet.* 97: 723-6 (1996)). It is probable that these five alleles are  
15 in linkage disequilibrium, although confirmation by statistical analyses has not yet been performed. Therefore, the IL-1 (44112332) haplotype may also include these five markers.

Similarly, Guasch found 3 additional alleles in IL1RN (Guasch, *et al.*, *Cytokine* 8: 598-602 (1997)) which appeared at the same frequencies in a small sample (12 individuals). One of the Guasch alleles (the MspI allele) is the 8006 allele of the Clay study. Therefore, the additional  
20 two alleles by Guasch (MwoI and SspI alleles) may be part of the IL-1 (4112332) haplotype discovered herein. However, this should be confirmed as described herein because the very small sample size may have produced misleading results.

Guasch also worked with three alleles in the IL1B gene. The alleles were allele 5887, which probably corresponds to the Taq allele at position +3953 of IL1B described herein, as  
25 well as a 5810 (BsoFI) allele and a 1903 (AluI) allele. These three alleles are said to be in "poor linkage disequilibrium" but accurate typing with a larger sample size may indicate that the AluI allele is also part of the IL-1 (4412332) haplotype since the allele frequencies of the TaqI and AluI

- 5 alleles are similar (0.78/0.22 vs. 0.74/0.26). However, the linkage disequilibrium appears weaker than the IL1RN alleles described by Guasch.

Therefore, in addition to the alleles identified herein, the IL-1 (44112332) haplotype may contain the following alleles:

|    |   |                                 |
|----|---|---------------------------------|
| 10 | allele 2 of the 1731 marker of the IL1RN gene | (A at position 1731)            |
|    | allele 2 of the 1812 marker of the IL1RN gene | (A at position 1812)            |
|    | allele 2 of the 1868 marker of the IL1RN gene | (G at position 1868)            |
|    | allele 2 of the 1887 marker of the IL1RN gene | (C at position 1887)            |
|    | allele 2 of the 8006 marker of the IL1RN gene | (contains a HpaII or MspI site) |
|    | allele 2 of the 8061 marker of the IL1RN gene | (lacks a MwoI site)             |
| 15 | allele 2 of the 9589 marker of the IL1RN gene | (contains an SspI site)         |

Furthermore, the following PCR primers may be used to amplify these alleles:

|    |                                       |                      |
|----|---------------------------------------|----------------------|
| 20 | TTACGCAGATAAGAACCAGTTTGG              | (SEQ ID NO. 17)      |
|    | TTTCCTGGACGCTTGCTCACCAG               | (SEQ ID NO. 18)      |
|    | (used for 1731, 1812, 1868, and 1887) |                      |
|    | TTCTATCTGAGGAACAACCAACTAGTAGC         | (SEQ ID NO. 19)      |
| 25 | CACCAGACTTGACACAGGACAGGCACATC         | (SEQ ID NO. 20)      |
|    | (used for 8006)                       |                      |
|    | CGACCCTCTGGGAGAAAATCCAGCAAG           | (SEQ ID NO. 21)      |
|    | (used with SEQ ID NO. 20 for 8006)    |                      |
| 30 | ACACAGGAAGGTGCCAAGCA                  | (SEQ ID NO. 22)      |
|    | TGCAGACAGACGGGCAAAGT                  | (SEQ ID NO. 23)      |
|    | (used for 8006 and 9589)              |                      |
| 35 | TTGTGGGGACCAGGGGAGAT                  | (SEQ ID NO. 24), and |
|    | AGCCTGGCACTCTGCTGAAT                  | (SEQ ID NO. 25)      |
|    | (used for 9589).                      |                      |

40

#### Example 4 The IL-1 (44112332) Haplotype is Associated with Diabetic Nephropathy

The presence of the two haplotypes described herein was investigated in healthy and diseased populations to determine if the haplotypes were associated with inflammatory disease. 81 non-insulin dependant diabetes mellitus (NIDDM) patients with nephropathy were compared with

5 198 ethnically matched healthy subjects in example 3 and 147 NIDDM patients without nephropathy. Genotyping was carried out as in example 1.

The IL-1 (44112332) haplotype was carried by 24 of 79 of the NIDDM nephropathy patients and 25 of 141 NIDDM without nephropathy patients. However, the second haplotype (33221461) was not found in the nephropathy patients (0/81). The IL-1 (44112332) haplotype was  
10 significantly over represented in the patient group compared with the healthy control group (24/79 vs. 34/198;  $p = 0.015$ ) and the NIDDM without nephropathy group (24/79 vs. 25/141;  $p = 0.03$ ). Therefore, the haplotype is associated with inflammatory disease.

**Example 5    An IL-1 Haplotype is Associated with Inflammatory Disease**

15            This is a prophetic example. Other diseases are examined as per Example 4. The IL-1 (44112332) haplotype is found to be associated with coronary artery disease, osteoporosis, nephropathy in diabetes mellitus, alopecia areata, Graves disease, systemic lupus erythematosus, lichen sclerosis and ulcerative colitis.

Likewise, the IL-1 (33221461) haplotype is associated with periodontal disease,  
20 juvenile chronic arthritis, psoriasis, insulin dependant diabetes and diabetic retinopathy.

**Example 6    Novel Markers are Linked to an IL-1 Haplotype**

This is a prophetic example. Additional markers are identified by sequence and restriction enzyme analysis of the 2q13-14 region. These new markers are identified as belonging  
25 to an IL-1 haplotype in the manner described in Examples 2 and 3.



5    **Example 7    The IL-1 (44112332) Haplotype Is Used to Predict Disease Susceptibility**

This is a prophetic example. A patient with a family history of ulcerative colitis is genotyped for the presence of the IL-1 (44112332) haplotype. Genotyping is performed as in Example 1 and the patient is determined to carry one or more alleles of the haplotype. The patient is thus treated with IL-1 antagonists to prevent disease.

10            A second patient with a family history of coronary artery disease is genotyped at the IL-1 gene cluster. The patient is found to carry one or more alleles of the IL-1 (44112332) haplotype and be homozygous for the VNTR allele 2. Thus, the patient is 5.4 times as likely to develop coronary artery disease as the general population and is treated vigorously to prevent disease.

15

**Example 8    Additional Haplotypes are Statistically Significant**

This is a prophetic example. An additional 400 chromosomes are typed as per Example 1 and linkage disequilibrium assessed as per Example 2. The IL-1 (33221461) haplotype is found to be present about 4 times more frequently than expected ( $p \sim 0.05$ ).

20            In a similar manner, the following markers are determined to be present in the IL-1 (44112332) haplotype ( $p \ll 0.05$ ).

25            allele 2 of the 1731 marker of the IL1RN gene  
             allele 2 of the 1812 marker of the IL1RN gene  
             allele 2 of the 1868 marker of the IL1RN gene  
             allele 2 of the 1887 marker of the IL1RN gene  
             allele 2 of the 8006 marker of the IL1RN gene  
             allele 2 of the 8061 marker of the IL1RN gene  
             allele 2 of the 9589 marker of the IL1RN gene

30            All documents cited herein are incorporated by reference and are separately listed here for convenience:

United States Patent No. 4,582,788

United States Patent No. 4,666,828

- 
- 5 United States Patent No. 4,801,531  
United States Patent No. 5,110,920  
United States Patent No. 5,268,267  
U.S. Application No. 08/813,416  
U.S. Application No. 08/628,282
- 10 GB Application No. 9618960.0  
Blakemore, *et al.*, *Hum. Genet.* **97**(3): 369-74 (1996)  
Blakemore, *et al.*, *J. Clin. Endocrinol.* **80**(1): 111-5 (1995)  
Blakemore, *et al.*, *Arthritis Rheum.* **37**: 1380-85 (1994)  
Clay, *et al.*, *Hum. Genet.* **97**: 723-6 (1996)
- 15 Clay, *et al.*, *Hum. Genet.* **94**: 407-10 (1994)  
di Giovine, *et al.*, *Hum. Molec. Genet.* **1**(6): 450 (1992)  
di Giovine, *et al.*, *Cytokine* **7**(6): 606 (1995)  
Guasch, *et al.*, *Cytokine* **8**: 598-602 (1997)  
Handbook of Human Genetic Linkage, 1994, John Hopkins University Press
- 20 Hill, *Heredity*, **33**: 229-39 (1974)  
Pociot, *et al.*, *Eur. J. Clin. Invest.* **22**: 396-402 (1992)  
Mansfield, *et al.*, *Gastroenterol.* **106**(3): 637-42 (1994)  
McDowell, *et al.*, *Br. J. Rheumatol.* **32**(Supp 1): 182 (1983)  
McDowell, *et al.*, *Arthritis Rheum.* **38**: 221-28 (1995)
- 25 Moling *et al.*, *Scand. J. Immunol.* **27**: 705-16 (1988)  
Nicklin, *et al.*, *Genomics* **19**: 382-4 (1994)  
Nothwang *et al.*, *Genomics* (*in press*)  
Pociot, *et al.*, *Eur. J. Clin. Invest.* **22**: 396-402 (1992)  
Spurr, *et al.*, *Cytogenet. & Cell Genet.* (*in press*, 1996)
- 30 Tarlow, *et al.*, *Hum. Genet.* **91**: 403-4 (1993)  
Tarlow, *et al.*, *J. Invest. Dermatol.* **103**: 387-90 (1994)  
Thompson, *et al.*, *Am. J. Hum. Genet.* **42**: 113-24 (1988)  
Todd & Naylor, *Nucleic Acids Res.* **19**: 3756 (1991)  
Weir, *et al.*, *Genet.* **88**: 633-42 (1976)
- 35 Wilson, *et al.*, *Hum. Molec. Genet.* **1**(5): 353 (1992)  
Xie and Ott, HANDBOOK OF HUMAN GENETIC LINKAGE, John Hopkins Un. Press, pp. 188-98 (1994)  
Zouros, *et al.*, *Genet.* **85**: 543-50 (1977)  
Zuliani, *et al.*, *Am. J. Hum. Genet.* **46**: 963-69 (1990)

## Claims

1. A method for determining a patient's susceptibility to an inflammatory disorder, said method comprising:
  - a. obtaining a biological sample from a patient; and
  - b. detecting the presence of an IL-1 (44112332) haplotype in said biological sample,  
wherein the presence of said IL-1 (44112332) haplotype indicates said patient's susceptibility to an inflammatory disorder.
2. The method of claim 1, wherein said inflammatory disorder is selected from the group consisting of coronary artery disease, osteoporosis, nephropathy in diabetes mellitus, alopecia areata, Graves disease, systemic lupus erythamatosus, lichen sclerosis, and ulcerative colitis.
3. The method of claim 1, wherein said detecting is done by amplifying said biological sample with PCR using at least one primer selected from the group consisting of:
 

|                               |                      |
|-------------------------------|----------------------|
| ATGTATAGAATTCCATTCTG          | (SEQ ID NO. 1),      |
| TAAATCAAGTGTTGATGTAG          | (SEQ ID NO. 2),      |
| GGGATTACAGGCGTGAGCCACCGCG     | (SEQ ID NO. 3),      |
| TTAGTATTGCTGGTAGTATTCATAT     | (SEQ ID NO. 4),      |
| TGTTCTACCACCTGAACTAGG         | (SEQ ID NO. 5),      |
| TTACATATGAGCCTTCCATG          | (SEQ ID NO. 6),      |
| CTCAGGTGTCCTCGAAGAAATCAAA     | (SEQ ID NO. 7),      |
| GCTTTTTTGCTGTGAGTCCCG         | (SEQ ID NO. 8),      |
| TGGCATTGATCTGGTTCATC          | (SEQ ID NO. 9),      |
| GTTTAGGAATCTTCCCACCT          | (SEQ ID NO. 10),     |
| GAGGCGTGAGAATCTCAAGA          | (SEQ ID NO. 11),     |
| GTGTCCTCAAGTGGATCTGG          | (SEQ ID NO. 12),     |
| GGGCAACAGAGCAATGTTTCT         | (SEQ ID NO. 13),     |
| CAGTGTGTCAAGTGTACTGT          | (SEQ ID NO. 14),     |
| CTCAGCAACACTCCTAT             | (SEQ ID NO. 15),     |
| TCCTGGTCTGCAGGTAA             | (SEQ ID NO. 16),     |
| TTACGCAGATAAGAACCAGTTTGG      | (SEQ ID NO. 17),     |
| TTTCCTGGACGCTTGCTCACCG        | (SEQ ID NO. 18),     |
| TTCTATCTGAGGAACAACCACTAGTAGC  | (SEQ ID NO. 19),     |
| CACCAGACTTGACACAGGACAGGCACATC | (SEQ ID NO. 20),     |
| CGACCTCTGGGAGAAAATCCAGCAAG    | (SEQ ID NO. 21),     |
| ACACAGGAAGGTGCCAAGCA          | (SEQ ID NO. 22),     |
| TGCAGACAGACGGGCAAAGT          | (SEQ ID NO. 23),     |
| TTGTGGGGACCAGGGGAGAT          | (SEQ ID NO. 24), and |
| AGCCTGGCACTCTGCTGAAT          | (SEQ ID NO. 25).     |

- 5 4. A diagnostic kit for the prediction of inflammatory disorder, said kit comprising at least one oligonucleotide selected from the group consisting of:

|    |                               |                      |
|----|-------------------------------|----------------------|
|    | ATGTATAGAATTCCATTCCTG         | (SEQ ID NO. 1),      |
|    | TAAAATCAAGTGTGATGTAG          | (SEQ ID NO. 2),      |
|    | GGGATTACAGGCGTGAGCCACCGCG     | (SEQ ID NO. 3),      |
| 10 | TTAGTATTGCTGGTAGTATTCATAT     | (SEQ ID NO. 4),      |
|    | TGTTCTACCACCTGAAGTAGG         | (SEQ ID NO. 5),      |
|    | TTACATATGAGCCTTCCATG          | (SEQ ID NO. 6),      |
|    | CTCAGGTGTCCTCGAAGAAATCAAA     | (SEQ ID NO. 7),      |
|    | GCTTTTTTGCTGTGAGTCCCG         | (SEQ ID NO. 8),      |
| 15 | TGGCATTGATCTGGTTCATC          | (SEQ ID NO. 9),      |
|    | GTTTAGGAATCTTCCCCTT           | (SEQ ID NO. 10),     |
|    | GAGGCGTGAGAATCTCAAGA          | (SEQ ID NO. 11),     |
|    | GTGTCCTCAAGTGGATCTGG          | (SEQ ID NO. 12),     |
|    | GGGCAACAGAGCAATGTTTCT         | (SEQ ID NO. 13),     |
| 20 | CAGTGTGTCAGTGTACTGTT          | (SEQ ID NO. 14),     |
|    | CTCAGCAACACTCCTAT             | (SEQ ID NO. 15),     |
|    | TCCTGGTCTGCAGGTAA             | (SEQ ID NO. 16),     |
|    | TTACGCAGATAAGAACCAGTTTGG      | (SEQ ID NO. 17),     |
| 25 | TTTCCTGGACGCTTGCTCACCAG       | (SEQ ID NO. 18),     |
|    | TTCTATCTGAGGAACAACCACTAGTAGC  | (SEQ ID NO. 19),     |
|    | CACCAGACTTGACACAGGACAGGCACATC | (SEQ ID NO. 20),     |
|    | CGACCCTCTGGGAGAAAATCCAGCAAG   | (SEQ ID NO. 21),     |
|    | ACACAGGAAGGTGCCAAGCA          | (SEQ ID NO. 22),     |
| 30 | TGCAGACAGACGGGCAAAGT          | (SEQ ID NO. 23),     |
|    | TTGTGGGGACCAGGGGAGAT          | (SEQ ID NO. 24), and |
|    | AGCCTGGCACTCTGCTGAAT          | (SEQ ID NO. 25).     |

- 35 5. The diagnostic kit of claim 4, further comprising a control sample.

6. The diagnostic kit of claim 5, wherein said control sample comprises one or more alleles selected from the group consisting of:

- 40 alleles of a 222/223 marker of IL1A;  
alleles of a gz5/gz6 marker of IL1A;  
alleles of a -889 marker of IL1A;  
alleles of a +3953 marker of IL1B;  
alleles of a -511 marker of IL1B;  
45 alleles of a gaat.p33330 marker;  
alleles of a Y31 marker;  
alleles of a VNTR marker of IL1RN;

- 5 alleles of a 1731 marker of IL1RN;  
alleles of a 1812 marker of IL1RN;  
alleles of a 1868 marker of IL1RN;  
alleles of a 1887 marker of IL1RN;  
alleles of a 8006 marker of IL1RN;  
10 alleles of a 8061 marker of IL1RN; and  
alleles of a 9589 marker of IL1RN.
7. The diagnostic kit of claim 4, wherein said oligonucleotide comprises a detectable label.
- 15 8. The diagnostic kit of claim 7, further comprising DNA sampling reagents, and PCR  
amplification reagents.
9. The diagnostic kit of claim 8, further comprising DNA sampling means.
- 20 10. A method of determining increased susceptibility to inflammatory disorder in a patient, said  
method comprising:  
a. obtaining DNA from a patient; and  
b. detecting a plurality of alleles from an IL-1 (44112332) haplotype in said  
DNA;  
25 wherein detecting said plurality of alleles indicates the patient's increased  
susceptibility to an inflammatory disorder.
11. The method of claim 10, whereby said plurality of alleles is selected from the group  
consisting of:  
30 allele 4 of a 222/223 marker of IL1A;  
allele 4 of a gz5/gz6 marker of IL1A;  
allele 1 of a -889 marker of IL1A;  
allele 1 of a +3953 marker of IL1B;  
allele 2 of a -511 marker of IL1B;

- 5 allele 3 of a gaat.p33330 marker;  
 allele 3 of a Y31 marker;  
 allele 2 of a VNTR marker of IL1RN;
- 10 allele 2 of a 1731 marker of IL1RN;  
 allele 2 of a 1812 marker of IL1RN;  
 allele 2 of a 1868 marker of IL1RN;  
 allele 2 of a 1887 marker of IL1RN;  
 allele 2 of a 8006 marker of IL1RN;  
 allele 2 of a 8061 marker of IL1RN; and
- 15 allele 2 of a 9589 marker of IL1RN.

12. The method of claim 11, wherein said detecting comprises PCR amplification of the DNA using a primer selected from the group consisting of:

- |    |                               |                      |
|----|-------------------------------|----------------------|
| 20 | ATGTATAGAATTCCATTCCTG         | (SEQ ID NO. 1),      |
|    | TAAAATCAAGTGTTGATGTAG         | (SEQ ID NO. 2),      |
|    | GGGATTACAGGCGTGAGCCACCGCG     | (SEQ ID NO. 3),      |
|    | TTAGTATTGCTGGTAGTATTCATAT     | (SEQ ID NO. 4),      |
|    | TGTTCTACCACCTGAACTAGG         | (SEQ ID NO. 5),      |
|    | TTACATATGAGCCTTCCATG          | (SEQ ID NO. 6),      |
| 25 | CTCAGGTGTCCTCGAAGAAATCAAA     | (SEQ ID NO. 7),      |
|    | GCTTTTTTGCTGTGAGTCCCG         | (SEQ ID NO. 8),      |
|    | TGGCATTGATCTGGTTCATC          | (SEQ ID NO. 9),      |
|    | GTTTAGGAATCTTCCCACTT          | (SEQ ID NO. 10),     |
|    | GAGGCGTGAGAATCTCAAGA          | (SEQ ID NO. 11),     |
| 30 | GTGTCCTCAAGTGGATCTGG          | (SEQ ID NO. 12),     |
|    | GGGCAACAGAGCAATGTTTCT         | (SEQ ID NO. 13),     |
|    | CAGTGTGTCAGTGTACTGTT          | (SEQ ID NO. 14),     |
|    | CTCAGCAACACTCCTAT             | (SEQ ID NO. 15),     |
|    | TCCTGGTCTGCAGGTAA             | (SEQ ID NO. 16),     |
| 35 | TTACGCAGATAAGAACCAGTTTGG      | (SEQ ID NO. 17),     |
|    | TTTCCTGGACGCTTGCTCACCAG       | (SEQ ID NO. 18),     |
|    | TTCTATCTGAGGAACAACCAACTAGTAGC | (SEQ ID NO. 19),     |
|    | CACCAGACTTGACACAGGACAGGCACATC | (SEQ ID NO. 20),     |
| 40 | CGACCCTCTGGGAGAAAATCCAGCAAG   | (SEQ ID NO. 21),     |
|    | ACACAGGAAGGTGCCAAGCA          | (SEQ ID NO. 22),     |
|    | TGCAGACAGACGGGCAAAGT          | (SEQ ID NO. 23),     |
|    | TTGTGGGGACCAGGGGAGAT          | (SEQ ID NO. 24), and |
| 45 | AGCCTGGCACTCTGCTGAAT          | (SEQ ID NO. 25).     |

5 13. The method of claim 7, wherein said inflammatory disorder is selected from the group consisting of coronary artery disease, osteoporosis, nephropathy in diabetes mellitus, alopecia areata, Graves disease, systemic lupus erythamatosus, lichen sclerosis, and ulcerative colitis.

10 14. A method of determining increased susceptibility to inflammatory disorder in a patient, said method comprising:

- a. obtaining DNA from a patient; and
- b. detecting a plurality of alleles from an IL-1 (33221461) haplotype in said DNA;

15 wherein detecting said plurality of alleles indicates the patient's increased susceptibility to an inflammatory disorder, and  
wherein said inflammatory disorder is selected from the group consisting of diabetic retinopathy, juvenile chronic arthritis, psoriasis, and insulin dependent diabetes.

20 15. The method of claim 14, wherein said plurality of alleles is selected from the group consisting of:

25 allele 3 of a 222/223 marker of IL1A;  
allele 3 of a gz5/gz6 marker of IL1A;  
allele 2 of a -889 marker of IL1A;  
allele 2 of a +3953 marker of IL1B;  
allele 1 of a -511 marker of IL1B;  
allele 4 of a gaat.p33330 marker;  
allele 6 of a Y31 marker; and  
allele 1 of a VNTR marker of IL1RN.

30

16. The method of claim 15, wherein said detecting comprises PCR amplification of the DNA using a primer selected from the group consisting of:

38

|    |                           |                      |
|----|---------------------------|----------------------|
| 5  | ATGTATAGAATTCCATTTCCTG    | (SEQ ID NO. 1),      |
|    | TAAAATCAAGTGTTGATGTAG     | (SEQ ID NO. 2),      |
|    | GGGATTACAGGCGTGAGCCACCGCG | (SEQ ID NO. 3),      |
|    | TTAGTATTGCTGGTAGTATTCATAT | (SEQ ID NO. 4),      |
|    | TGTTCTACCACCTGAACTAGG     | (SEQ ID NO. 5),      |
| 10 | TTACATATGAGECTTCCATG      | (SEQ ID NO. 6),      |
|    | CTCAGGTGTCCTCGAAGAAATCAAA | (SEQ ID NO. 7),      |
|    | GCTTTTTTGTCTGTGAGTCCCG    | (SEQ ID NO. 8),      |
|    | TGGCATTGATCTGGTTCATC      | (SEQ ID NO. 9),      |
|    | GTTTAGGAATCTTCCCCTT       | (SEQ ID NO. 10),     |
| 15 | GAGGCGTGAGAATCTCAAGA      | (SEQ ID NO. 11),     |
|    | GTGTCCTCAAGTGGATCTGG      | (SEQ ID NO. 12),     |
|    | GGGCAACAGAGCAATGTTTCT     | (SEQ ID NO. 13),     |
|    | CAGTGTGTCAGTGTACTGTT      | (SEQ ID NO. 14),     |
|    | CTCAGCAACACTCCTAT         | (SEQ ID NO. 15), and |
| 20 | TCCTGGTCTGCAGGTAA         | (SEQ ID NO. 16).     |

17. A method of predicting increased susceptibility to inflammatory disorder in a patient, said method comprising:
- a. obtaining DNA from a patient; and
  - b. detecting one or more alleles from the group consisting of:
    - allele 4 of a 222/223 marker of IL1A;
    - allele 4 of a gz5/gz6 marker of IL1A;
    - allele 1 of a -889 marker of IL1A;
    - allele 1 of a +3953 marker of IL1B;
    - allele 2 of a -511 marker of IL1B;
    - allele 3 of a gaat.p33330 marker;
    - allele 3 of a Y31 marker;
    - allele 2 of a 1731 marker of the IL1RN gene;
    - allele 2 of a 1812 marker of the IL1RN gene;
    - allele 2 of a 1868 marker of the IL1RN gene;
    - allele 2 of a 1887 marker of the IL1RN gene;
    - allele 2 of a 8006 marker of the IL1RN gene;
    - allele 2 of a 8061 marker of the IL1RN gene; and
    - allele 2 of a 9589 marker of the IL1RN gene,
- wherein detecting said one or more alleles indicates increased susceptibility to an inflammatory disorder, and



5                    wherein said inflammatory disorder is selected from the group consisting of  
coronary artery disease, osteoporosis, nephropathy in diabetes mellitus, alopecia  
areata, Graves disease, systemic lupus erythamatosus, lichen sclerosis, and  
ulcerative colitis.

10 18.        The method of claim 17, wherein said detecting comprises PCR amplification of the DNA  
using a primer selected from the group consisting of:

|                              |                  |
|------------------------------|------------------|
| ATGTATAGAATTCCATTCTG         | (SEQ ID NO. 1),  |
| TAAAATCAAGTGTTGATGTAG        | (SEQ ID NO. 2),  |
| GGGATTACAGGCGTGAGCCACCGCG    | (SEQ ID NO. 3),  |
| 15 TTAGTATTGCTGGTAGTATTCATAT | (SEQ ID NO. 4),  |
| TGTTCTACCACCTGAACTAGG        | (SEQ ID NO. 5),  |
| TTACATATGAGCCTTCCATG         | (SEQ ID NO. 6),  |
| CTCAGGTGTCCTCGAAGAAATCAAA    | (SEQ ID NO. 7),  |
| GCTTTTTTTGCTGTGAGTCCCG       | (SEQ ID NO. 8),  |
| 20 TGGCATTGATCTGGTTCATC      | (SEQ ID NO. 9),  |
| GTTTAGGAATCTTCCCCTT          | (SEQ ID NO. 10), |
| GAGGCGTGAGAATCTCAAGA         | (SEQ ID NO. 11), |
| GTGTCCTCAAGTGGATCTGG         | (SEQ ID NO. 12), |
| GGGCAACAGAGCAATGTTTCT        | (SEQ ID NO. 13), |
| 25 CAGTGTGTCAGTGTACTGTT      | (SEQ ID NO. 14), |
| CTCAGCAACACTCCTAT            | (SEQ ID NO. 15), |
| TCCTGGTCTGCAGGTAA            | (SEQ ID NO. 16), |

|                               |                      |
|-------------------------------|----------------------|
| TTACGCAGATAAGAACCAGTTTGG      | (SEQ ID NO. 17),     |
| 30 TTTCCTGGACGCTTGCTCACCAG    | (SEQ ID NO. 18),     |
| TTCTATCTGAGGAACAACCACTAGTAGC  | (SEQ ID NO. 19),     |
| CACCAGACTTGACACAGGACAGGCACATC | (SEQ ID NO. 20),     |
| CGACCCTCTGGGAGAAAATCCAGCAAG   | (SEQ ID NO. 21),     |
| ACACAGGAAGGTGCCAAGCA          | (SEQ ID NO. 22),     |
| 35 TGCAGACAGACGGGCAAAGT       | (SEQ ID NO. 23),     |
| TTGTGGGGACCAGGGGAGAT          | (SEQ ID NO. 24), and |
| AGCCTGGCACTCTGCTGAAT          | (SEQ ID NO. 25).     |

19.        A method of predicting increased susceptibility to inflammatory disorder in a patient, said  
40 method comprising:

a.        obtaining DNA from a patient; and

- 5                   b.       detecting one or more alleles from the group consisting of:

allele 3 of a 222/223 marker of IL1A;  
 allele 3 of a gz5/gz6 marker of IL1A;  
 allele 1 of a -511 marker of IL1B;  
 allele 4 of a -3330 marker;  
 allele 6 of a Y31 marker; and  
 allele 1 of a VNTR marker of IL1RN,

10

wherein detecting said one or more alleles indicates increased susceptibility to an  
 inflammatory disorder, and

15

wherein said inflammatory disorder is selected from the group consisting of  
 diabetic retinopathy, periodontal disease, juvenile chronic arthritis, psoriasis, and  
 insulin dependent diabetes.

20.   The method of claim 13, wherein said detecting comprises PCR amplification of the DNA  
 20       using a primer selected from the group consisting of:


|    |                           |                  |
|----|---------------------------|------------------|
|    | ATGTATAGAATTCCATTCCTG     | (SEQ ID NO. 1),  |
|    | TAAAATCAAGTGTTGATGTAG     | (SEQ ID NO. 2),  |
|    | GGGATTACAGGCGTGAGCCACCGCG | (SEQ ID NO. 3),  |
|    | TTAGTATTGCTGGTAGTATTCATAT | (SEQ ID NO. 4),  |
| 25 | TGTTCTACCACCTGAAGTAGG     | (SEQ ID NO. 5),  |
|    | TTACATATGAGCCTTCCATG      | (SEQ ID NO. 6),  |
|    | CTCAGGTGTCCTCGAAGAAATCAAA | (SEQ ID NO. 7),  |
|    | GCTTTTTTGCTGTGAGTCCCG     | (SEQ ID NO. 8),  |
|    | TGGCATTGATCTGGTTCATC      | (SEQ ID NO. 9),  |
| 30 | GTTTAGGAATCTTCCCCTT       | (SEQ ID NO. 10), |
|    | GAGGCGTGAGAATCTCAAGA      | (SEQ ID NO. 11), |
|    | GTGTCCTCAAGTGGATCTGG      | (SEQ ID NO. 12), |
|    | GGGCAACAGAGCAATGTTTCT     | (SEQ ID NO. 13), |
|    | CAGTGTGTCAGTGTACTGTT      | (SEQ ID NO. 14), |
| 35 | CTCAGCAACACTCCTAT         | (SEQ ID NO. 15), |
|    | TCCTGGTCTGCAGGTAA         | (SEQ ID NO. 16), |

21.   A method of identifying additional markers in an IL-1 haplotype, said method comprising:  
 40       a.       identifying a marker from an IL-1 gene cluster,  
           b.       measuring the frequency of occurrence of said marker and determining the  
                   degree of disequilibrium with an IL-1 haplotype.
22.   The method of claim 21, wherein said IL-1 haplotype is the IL-1 (44112332) haplotype.

- 5 23. The method of claim 21, wherein said IL-1 haplotype is the IL-1 (33221461) haplotype.
24. A method of identifying additional inflammatory disorders associated with alleles in an IL-1 haplotype, said method comprising:
- a. gathering a first group of patient's with an inflammatory disease;
  - 10 b. gathering a second group of patient's without said inflammatory disease; and
  - c. identifying an allele from an IL-1 haplotype in the first and second groups,
- wherein over representation of said allele in the first group as compared with the second group indicates that said allele is associated with said inflammatory disease.
- 15 25. The method of claim 24, wherein said IL-1 haplotype is the IL-1 (44112332) haplotype.
26. The method of claim 24, wherein said IL-1 haplotype is the IL-1 (33221461) haplotype.
27. An allelic ladder for use in DNA typing, said allelic ladder comprising a plurality of alleles
- 20 selected from the group consisting of:
- alleles of a 222/223 marker of IL1A;
  - alleles of a gz5/gz6 marker of IL1A;
  - alleles of a -889 marker of IL1A;
  - alleles of a +3953 marker of IL1B;
  - 25 alleles of a -511 marker of IL1B;
  - alleles of a gaat.p33330 marker;
  - alleles of a Y31 marker;
  - alleles of a VNTR marker of IL1RN;
  - 30 alleles of a 1731 marker of the IL1RN;
  - alleles of a 1812 marker of the IL1RN;
  - alleles of a 1868 marker of the IL1RN;
  - alleles of a 1887 marker of the IL1RN;
  - alleles of a 8006 marker of the IL1RN;
  - 35 alleles of a 8061 marker of the IL1RN; and
  - alleles of a 9589 marker of the IL1RN.

1/2


FIGURE 1



Polymorphic loci in the IL-1 gene cluster.

2/2

FIGURE 2



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/01481

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C1201/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C120

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|----------|--|-----------------------|
| X        | MCDOWELL T.L. ET AL.,: "A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism"<br>ARTHRITIS & RHEUMATISM,<br>vol. 38, no. 2, - February 1995 pages 221-228, XP002077314<br>cited in the application<br>see whole doc. esp primers page 222<br>--- | 1-27                  |
| X        | DI GIOVINE F.S. ET AL.,: "Single base polymorphism at -511 in the human interleukin-1beta gene (IL1beta)"<br>HUMAN MOLECULAR GENETICS,<br>vol. 1, no. 6, - September 1992 page 450<br>XP002077315<br>cited in the application<br>see the whole document<br>---                                       | 1-27                  |

-/--



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 September 1998

Date of mailing of the international search report

25/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Müller, F

# INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/GB 98/01481

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|----------|---|-----------------------|
| X        | CLAY F. E. ET AL.,: "Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment"<br>HUM. GENET.,<br>vol. 97, - June 1996 pages 723-726,<br>XP002077312<br>cited in the application<br>see whole doc. esp. materials and methods<br>see the whole document<br>--- | 1-27                  |
| A        | EPPLEN C. ET AL.,: "Dinucleotide repeat polymorphism in the human IL1A gene"<br>HUMAN MOLECULAR GENETICS,<br>vol. 3, no. 9, - September 1994 page 1710<br>XP002077310<br>see the whole document<br>---  | 1-27                  |
| A        | GUASCH J. F. ET AL.,: "Five novel intragenic dimorphisms in the human interleukin-1 genes combine to high informativity"<br>CYTOKINE,<br>vol. 8, no. 8, - August 1996 pages 598-602, XP002077311<br>see the whole document<br>---   | 1-27                  |
| A        | BAILLY S. ET AL.,: "Genetic polymorphism of human interleukin-1alpha"<br>EUR. J. IMMUNOL.,<br>vol. 23, - June 1993 pages 1240-1245,<br>XP002077313<br>see the whole document<br>---   | 1-27                  |
| A        | TODD S. & NAYLOR S.L.: "Dinucleotide repeat polymorphism in the human interleukin 1, alpha gene (IL1A)"<br>NUCLEIC ACIDS RESEARCH,<br>vol. 19, no. 13, - 1991 page 373756<br>XP002077341<br>cited in the application<br>see the whole document<br>---   | 1-27                  |
| P,A      | WO 97 38135 A (MEDICAL SCIENCE SYSTEMS INC) 16 October 1997<br>see the whole document<br>---  | 1-27                  |
| P,A      | WO 97 43446 A (GEMINI INTERNATIONAL HOLDINGS ;RALSTON STUART HAMILTON (GB); GRANT) 20 November 1997<br>see the whole document<br>---  | 1-27                  |
|          | -/--  |                       |

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/01481

## C.(Continuation)-DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| P,A        | WO 98 15653 A (RICHARDSON ROBERT ;DUFF<br>GORDON (GB); RENNIE IAN (GB))<br>16 April 1998<br>see the whole document  | 1-27                  |
| P,X        | COX A. ET AL.,: "AN analysis of linkage<br>disequilibrium in the interleukin-1 gene<br>cluster, using a novel grouping method for<br>multiallelic markers"<br>AM. J. HUM. GENET. ,<br>vol. 62, - May 1998 pages 1180-1188,<br>XP002077316<br>see the whole document | 1-27                  |



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/01481

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)                   | Publication<br>date                    |
|---|---------------------|--|--|
| W0 9738135 A                              | 16-10-1997          | US 5698399 A<br>AU 2607797 A<br>EP 0832298 A | 16-12-1997<br>29-10-1997<br>01-04-1998 |
| W0 9743446 A                              | 20-11-1997          | AU 2904197 A                                 | 05-12-1997                             |
| W0 9815653 A                              | 16-04-1998          | AU 4631197 A                                 | 05-05-1998                             |

**THIS PAGE BLANK (USPTO)**